These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 38050977)

  • 1. CRISPR-Based Approaches for Cancer Immunotherapy.
    Malla RR; Middela K
    Crit Rev Oncog; 2023; 28(4):1-14. PubMed ID: 38050977
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Innovative Strategies of Reprogramming Immune System Cells by Targeting CRISPR/Cas9-Based Genome-Editing Tools: A New Era of Cancer Management.
    Allemailem KS; Alsahli MA; Almatroudi A; Alrumaihi F; Al Abdulmonem W; Moawad AA; Alwanian WM; Almansour NM; Rahmani AH; Khan AA
    Int J Nanomedicine; 2023; 18():5531-5559. PubMed ID: 37795042
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The application of CRISPR-Cas9 genome editing tool in cancer immunotherapy.
    Wu HY; Cao CY
    Brief Funct Genomics; 2019 Mar; 18(2):129-132. PubMed ID: 29579146
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CRISPR/Cas9 and CAR-T cell, collaboration of two revolutionary technologies in cancer immunotherapy, an instruction for successful cancer treatment.
    Mollanoori H; Shahraki H; Rahmati Y; Teimourian S
    Hum Immunol; 2018 Dec; 79(12):876-882. PubMed ID: 30261221
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Applications and advances of CRISPR-Cas9 in cancer immunotherapy.
    Xia AL; He QF; Wang JC; Zhu J; Sha YQ; Sun B; Lu XJ
    J Med Genet; 2019 Jan; 56(1):4-9. PubMed ID: 29970486
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Integration of CRISPR/Cas9 with artificial intelligence for improved cancer therapeutics.
    Bhat AA; Nisar S; Mukherjee S; Saha N; Yarravarapu N; Lone SN; Masoodi T; Chauhan R; Maacha S; Bagga P; Dhawan P; Akil AA; El-Rifai W; Uddin S; Reddy R; Singh M; Macha MA; Haris M
    J Transl Med; 2022 Nov; 20(1):534. PubMed ID: 36401282
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CRISPR-cas9 genome editing delivery systems for targeted cancer therapy.
    Ghaemi A; Bagheri E; Abnous K; Taghdisi SM; Ramezani M; Alibolandi M
    Life Sci; 2021 Feb; 267():118969. PubMed ID: 33385410
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CRISPR/Cas9 application in cancer therapy: a pioneering genome editing tool.
    Shojaei Baghini S; Gardanova ZR; Abadi SAH; Zaman BA; İlhan A; Shomali N; Adili A; Moghaddar R; Yaseri AF
    Cell Mol Biol Lett; 2022 May; 27(1):35. PubMed ID: 35508982
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CRISPR/Cas9: A revolutionary genome editing tool for human cancers treatment.
    Akram F; Haq IU; Sahreen S; Nasir N; Naseem W; Imitaz M; Aqeel A
    Technol Cancer Res Treat; 2022; 21():15330338221132078. PubMed ID: 36254536
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination of CRISPR/Cas9 System and CAR-T Cell Therapy: A New Era for Refractory and Relapsed Hematological Malignancies.
    Hu KJ; Yin ETS; Hu YX; Huang H
    Curr Med Sci; 2021 Jun; 41(3):420-430. PubMed ID: 34218353
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CRISPR-Cas9, A Promising Therapeutic Tool for Cancer Therapy: A Review.
    Akram F; Ikram Ul Haq ; Ahmed Z; Khan H; Ali MS
    Protein Pept Lett; 2020; 27(10):931-944. PubMed ID: 32264803
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Critical cancer vulnerabilities identified by unbiased CRISPR/Cas9 screens inform on efficient cancer Immunotherapy.
    Potts MA; McDonald JA; Sutherland KD; Herold MJ
    Eur J Immunol; 2020 Dec; 50(12):1871-1884. PubMed ID: 33202035
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Engineered Nanomaterials to Potentiate CRISPR/Cas9 Gene Editing for Cancer Therapy.
    Yi K; Kong H; Lao YH; Li D; Mintz RL; Fang T; Chen G; Tao Y; Li M; Ding J
    Adv Mater; 2024 Mar; 36(13):e2300665. PubMed ID: 37437039
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genome-wide CRISPR screens for the identification of therapeutic targets for cancer treatment.
    Xue VW; Wong SCC; Cho WCS
    Expert Opin Ther Targets; 2020 Nov; 24(11):1147-1158. PubMed ID: 32893711
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CRISPR-Cas9 for cancer therapy: Opportunities and challenges.
    Chen M; Mao A; Xu M; Weng Q; Mao J; Ji J
    Cancer Lett; 2019 Apr; 447():48-55. PubMed ID: 30684591
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current applications and future perspective of CRISPR/Cas9 gene editing in cancer.
    Wang SW; Gao C; Zheng YM; Yi L; Lu JC; Huang XY; Cai JB; Zhang PF; Cui YH; Ke AW
    Mol Cancer; 2022 Feb; 21(1):57. PubMed ID: 35189910
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Engineering T Cells Using CRISPR/Cas9 for Cancer Therapy.
    Zhang X; Cheng C; Sun W; Wang H
    Methods Mol Biol; 2020; 2115():419-433. PubMed ID: 32006414
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CRISPR/Cas: From Tumor Gene Editing to T Cell-Based Immunotherapy of Cancer.
    Azangou-Khyavy M; Ghasemi M; Khanali J; Boroomand-Saboor M; Jamalkhah M; Soleimani M; Kiani J
    Front Immunol; 2020; 11():2062. PubMed ID: 33117331
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CRISPR/Cas9-Mediated Genome Editing in Cancer Therapy.
    Ding S; Liu J; Han X; Tang M
    Int J Mol Sci; 2023 Nov; 24(22):. PubMed ID: 38003514
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CRISPR technology for immuno-oncology applications.
    Wang J; Balan V; Marincola F
    Methods Enzymol; 2020; 635():251-266. PubMed ID: 32122549
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.